We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Decision Resources Announces Electronic Format for the Spectrum Report Series
News

Decision Resources Announces Electronic Format for the Spectrum Report Series

Decision Resources Announces Electronic Format for the Spectrum Report Series
News

Decision Resources Announces Electronic Format for the Spectrum Report Series

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Decision Resources Announces Electronic Format for the Spectrum Report Series "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Decision Resources has announced that it has found that leading pharmaceutical companies that manufacture and market monoclonal antibodies (MAbs) are targeting smaller companies for acquisition in order to obtain the promising technology in the development of MAbs.

The Spectrum report Industry Analysis - How Companies Can Maintain the Market Success of Cancer MAbs finds that smaller, cash-poor companies on the leading edge of MAb development face an uncertain future as they will likely become acquisition targets and be forced to decide whether to attempt survival on licensing and royalties or to pursue their own product development.

MAb-driven mergers over the past year include Amgen's acquisition of Abgenix, AstraZeneca's purchase of Cambridge Antibody Technology, and Merck's acquisition of Abmaxis.

The report also finds that the premium pricing of monoclonal antibodies could cause significant marketing problems for drug developers in the years ahead.

"Cancer-targeting MAbs continue to push the limits in this market," said Matt Drapeau, an author of the report.

"Their ever-soaring prices indicate that the breaking point is fast upon us. Payers must decide whether to reimburse potentially life-saving new treatments while wrestling with the reality of extraordinarily high priced MAbs."

"This situation does not bode well for drug manufacturers and could cause a backlash against the industry."

Industry Analysis - How Companies Can Maintain the Market Success of Cancer MAbs is the first Spectrum report available in Decision Resources' Spectrum online format.

The features of Spectrum online include easier navigation within reports, enhanced abstracts, and executive summaries.

Spectrum's report abstracts, tables of contents, and executive summaries highlight:

- Comprehensive descriptions of report scope including companies mentioned

- Business implications that pinpoint the report's most relevant audiences

- Key strategic issues addressed in each report, tailored to specific stakeholder groups

- Key tables and figures and related Spectrum reports

- Expertise of the author(s) and Decision Resources' program managers

- Forward-looking quotes from Decision Resources' program managers and their biographies

Advertisement